Clinical Trial Update: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 study evaluating BGB-11417 monotherapy in participants with relapsed or refractory Mantle Cell Lymphoma; the trial is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• BGB-11417

Snippet

Sponsor: BeiGene | Conditions: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING